Saniona completes SAN2465 tox, CMC studies, targets IND filing by end — October 2026

Saniona completed toxicology and CMC work for SAN2465, clearing the package needed to support an IND filing. IND submission to the FDA is targeted by end-October 2026, setting up first-in-human dosing plans. Planned Phase 1 trial targets safety, tolerability, pharmacokinetics in healthy volunteers, with biomarker readouts to inform dose selection. SAN2465 targets GABA-A α5 receptors for major depressive disorder, aiming for ketamine-like rapid onset with an oral profile. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein. (C)